At any given time there are a large number of clinical trials taking place at Nationwide Children’s that offer state-of-the-art therapies and additional treatment options to your child.
Biospecimen Core Resource
Nationwide Children’s is processing tumor and tissue for The Cancer Genome Atlas, the nation’s largest cancer genome study. Learn more about our role as a Biospecimen Core Resource.
Pediatric Tumor Bank
Neuroblastoma Biomarker Predicts Cancer Severity Risk
Researchers have identified a biomarker that may help classify patients with more aggressive neuroblastoma, regardless of age-based risk categories.
Anti-Angiogenic Measles Virus Offers Hope for Medulloblastoma Treatment
Researchers further improve a viral therapy for medulloblastoma by adding anti-angiogenic proteins.
Research Helps Demystify Sickle Cell Disease
Research is shedding light on issues in pediatric sickle cell patients, from acute chest syndrome to social skills.
Anticoagulation Clinic Offers Streamlined Treatment
Patients receiving anticoagulation therapy can now obtain blood tests and medication adjustments in a single visit.
MIBG Treatment Now Available
State-of-the-art treatment room for MIBG patients offers twelfth floor views and an attached parent room.
2013 Inroads in Pediatric Cancer Research
Research highlights from Hematology/Oncology/BMT includes advanced viral therapy, preclinical testing, chemotherapy and tumor suppression.
Unraveling Tumor Angiogenesis
Recent study shows the role of ΔNp63 in tumor growth and cancer cell proliferation in childhood cancers.
Treating Pediatric Cancer with Viral Therapy
Researchers to launch phase I clinical trial that will study viral therapy treatment for cancers such as neuroblastoma and sarcoma.
Potential Therapy for NF2 Tumors
Two plant-derived compounds may stunt tumor growth in NF2, a disorder that affects one in every 25,000 Americans
$6.3 Million Grant Furthers Childhood Sarcoma Research
Researchers to develop novel therapeutic approaches for pediatric sarcomas, which account for 11 percent of childhood cancers.